Company intelligence / Profile preview

ADEL Inc.

Ownership: Private
Development stage: Phase 1

Overview

ADEL Inc. is advancing ADEL-Y01, a tau antibody-based therapy currently in a U.S.-based Phase I study. The company is focused on developing treatments for Alzheimer's disease by targeting tau protein accumulation in the brain.

Therapeutic areas: Metabolic DisordersOncologyImmunologyOtherNeurology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Drug pipeline

2 assets

ADEL-Y-04

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Oscotec

Beyond the preview

Go deeper on ADEL Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADEL Inc..

Explore the full profile